numares announces FDA 510(k) Submission of AXINON System ® , a NMR platform for metabolomics-based, AI-driven Diagnostics
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System, a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, refined by numares' proprietary Magnetic Group SignalingTM, allows metabolomics-based precision diagnostics by implementation of various numares' tests, e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR) and risk for cardiovascular disease (CVD). (Photo: Business Wire)
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares," said Winton Gibbons, President - US and co-Chief Executive Officer of numares. “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON®IVD System. These include AXINON®GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON®renalTX-SCORE®is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software, ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON®System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS®) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
Contact information
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail: christiane.proll@numares.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 09:00:00 CEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,
Bots Now Make Up Nearly Half of All Internet Traffic Globally16.4.2024 09:00:00 CEST | Press release
Thales, the cybersecurity leader that protects critical applications, APIs, and data, anywhere at scale, today announced the release of the 2024 Imperva Bad Bot Report, a global analysis of automated bot traffic across the internet. Nearly half (49.6%) of all internet traffic came from bots in 2023—a 2% increase over the previous year, and the highest level Imperva has reported since it began monitoring automated traffic in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416225637/en/ ©Thales For the fifth consecutive year, the proportion of web traffic associated with bad bots grew to 32% in 2023, up from 30.2% in 2022, while traffic from human users decreased to 50.4%. Automated traffic is costing organizations billions (USD) annually due to attacks on websites, APIs, and applications. “Bots are one of the most pervasive and growing threats facing every industry,” says Nanhi Singh, General Manager, Application Secu
Money20/20 Europe Unveils 2024 Speaker Lineup Under ‘Human X Machine’ Show Theme16.4.2024 09:00:00 CEST | Press release
Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands. Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper an
FPT Commits to Sustainable Development, Aligning with ESG Standards16.4.2024 08:22:00 CEST | Press release
As part of its ongoing commitment to the highest standards of sustainable development, FPT Corporation (FPT) has published its ESG report and prioritized ESG as a key aspect of its 2024 development strategy. The report highlights FPT’s achievement of 87% positive employee feedback, certified by Great Place to Work® - a significantly higher rating than a typical global company’s average of 53%. The Corporation is also certified among Vietnam's Top 10 Best Large-Scale Workplaces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415745348/en/ Happy Run race is one of FPT’s social responsibility activities (Photo: Business Wire) “In 2023, I described FPT as a joyful sanctuary. I delineated the concept wherein FPT assumed the role of building a happier future for shareholders, customers, and employees. This depiction has begun to manifest itself into reality,” said FPT Chairman Dr. Truong Gia Binh. FPT’s ESG commitment is reflec
Neura Robotics and OMRON Forge Strategic Alliance to Revolutionize the Manufacturing Industry with Cognitive Robots16.4.2024 08:10:00 CEST | Press release
Neura Robotics, a global pioneer in cognitive robotics, and Omron Robotics and Safety Technologies Inc., a global leader in industrial robotics and automation, are excited to announce their strategic partnership. This partnership aims to revolutionize the manufacturing industry by introducing cognitive robots into factory automation, leveraging advanced AI capabilities to enhance efficiency, flexibility, and safety. Unlike traditional industrial robots, cognitive robots have the ability to learn from their environment, make decisions autonomously, and adapt to dynamic production scenarios. This opens new application possibilities including intricate assembly tasks, detailed quality inspections, and adaptive material handling processes. Olivier Welker, President and CEO of Omron Robotics and Safety Technologies Inc., emphasizes the significance of this partnership, stating, "We see Neura's cognitive technologies as a compelling growth opportunity for industrial robotics. By combining Ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom